Gilead Sciences Inc. logo

Gilead Sciences Inc. (GILD)

Market Closed
1 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
149. 92
+3.58
+2.4464%
$
181.69B Market Cap
17.2 P/E Ratio
0.42% Div Yield
4.83M Volume
6.22 Eps
$ 146.34
Previous Close
Add Transaction
Day Range
146.91 149.96
Year Range
108.46 157.29
Want to track GILD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.

Zacks | 1 year ago
Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
EU regulator backs Gilead's twice-yearly injection for HIV prevention

EU regulator backs Gilead's twice-yearly injection for HIV prevention

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said on Friday.

Reuters | 1 year ago
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.

Zacks | 1 year ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks | 1 year ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.

Zacks | 1 year ago
WHO recommends Gilead's twice-yearly injection for HIV prevention

WHO recommends Gilead's twice-yearly injection for HIV prevention

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Reuters | 1 year ago
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.

Zacks | 1 year ago
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 1 year ago
Loading...
Load More